التفاصيل البيبلوغرافية
| العنوان: |
The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities. |
| المؤلفون: |
Varela‐Calviño, Rubén, Rodríguez‐Quiroga, Marta, Dias Carvalho, Patrícia, Martins, Flavia, Serra‐Roma, André, Vázquez‐Iglesias, Lorena, Páez de la Cadena, María, Velho, Sérgia, Cordero, Oscar J. |
| المصدر: |
IUBMB Life; May2021, Vol. 73 Issue 5, p761-773, 13p |
| مصطلحات موضوعية: |
COLORECTAL cancer, CANCER cell motility, CELL lines, SITAGLIPTIN, CHEMOTAXIS, CANCER stem cells, TRANSFORMING growth factors, IRINOTECAN |
| مستخلص: |
The cell membrane glycoprotein CD26 with peptidase activity (DPP4) and/or its soluble CD26/DPP4 counterpart expression and/or activity are altered in several cancers. Its role in metastasis development was recently highlighted by the discovery of CD26+ cancer stem cell subsets and the fact that clinical DPP4 inhibitors showed antimetastatic effects in animal models. Also, diabetic patients treated with the DPP4 inhibitor sitagliptin showed greater overall survival after colorectal or lung cancer surgery than patients under other diabetic therapies. However, the mechanism of action of these inhibitors in this context is unclear. We studied the role of CD26 and its DPP4 enzymatic activity in malignant cell features such as cell‐to‐cell homotypic aggregation, cancer cell motility, and invasion in a panel of human colorectal cancer (CRC) cell lines, avoiding models that include the physiological role of DPP4 in chemotaxis. Present results indicate that CD26 participates in the induction of cell invasion, motility, and aggregation of CD26‐positive CRC cell lines. Moreover, only invasion and motility assays, which are collagen matrix‐dependent, showed a decrease upon treatment with the DPP4 inhibitor sitagliptin. Sitagliptin showed opposite effects to those of transforming growth factor‐β1 on epithelial‐to‐mesenchymal transition and cell cycle, but this result does not explain its CD26/DPP4‐dependent effect. These results contribute to the elucidation of the molecular mechanisms behind sitagliptin inhibition of metastatic traits. At the same time, this role of sitagliptin may help to define areas of medicine where DPP4 inhibitors might be introduced. However, they also suggest that additional tools against CD26 as a target might be used or developed for metastasis prevention in addition to gliptins. [ABSTRACT FROM AUTHOR] |
|
Copyright of IUBMB Life is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder